Methylenetetrahydrofolate Reductase Gene Polymorphism, Homocysteine and Risk of Macroangiopathy in Type 2 Diabetes Mellitus

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2006 Nov 23

PMID 17114913

Citations 3

Authors

J Sun

Y Xu

Y Zhu

H Lu

Affiliations

Soon will be listed here.

Abstract

Objective: A polymorphism in the gene for methylenetetrahydrofolate reductase (MTHFR) has been reported to be associated with hyperhomocysteinemia and risk for atherosclerotic vascular diseases. In this case-control study, we examined the distribution of the MTHFR genotypes in the Chinese population and clarified the relationship between the gene polymorphism for MTHFR and macroangiopathy in Chinese Type 2 diabetes mellitus.

Methods: Two hundred and sixteen unrelated patients with Type 2 diabetes mellitus, 112 of whom had macroangiopathy, and 114 healthy control subjects, were recruited. The MTHFR C677T genotype was analyzed by polymerase chain reaction-restriction fragment length polymorphism. Plasma total homocysteine levels were measured using high-performance liquid chromatography (HPLC) with fluorescence detection.

Results: In 114 healthy control subjects, the frequency of the mutant T allele was 31.1%. The genotype distribution did not differ between control subjects and Type 2 diabetic patients (chi2=3.03, p=0.220). Genotypic analysis revealed that the MTHFR genotype was different between diabetic patients with and without macroangiopathy (chi2=12.42, p=0.002). Type 2 diabetic patients with macroangiopathy displayed a greater prevalence of T allele than Type 2 diabetic patients without macroangiopathy (44.6 vs 29.3%; chi2=10.82, p=0.001). The odds ratio for macroangiopathy in Type 2 diabetic patients in presence of T allele was 1.94 [confidence interval (CI) 95%: 1.31-2.89]. Moreover, plasma homocysteine levels were markedly higher in individuals with TT genotype than those with CC or CT genotype.

Conclusions: The C677T mutation of MTHFR gene is common in the Chinese population. MTHFR C677T gene polymorphism associated with a predisposition to increased plasma homocysteine levels could constitute a useful predictive marker for macroangiopathy in Chinese Type 2 diabetic patients.

Citing Articles

Role of metabolizing MTHFR gene polymorphism (rs1801133) and its mRNA expression among Type 2 Diabetes.

Pathak D, Shrivastav D, Verma A, Alsayegh A, Yadav P, Khan N J Diabetes Metab Disord. 2022; 21(1):511-516.

PMID: 35673506 PMC: 9167251. DOI: 10.1007/s40200-022-01001-7.

Impact of KCNJ11 rs5219, UCP2 rs659366, and MTHFR rs1801133 Polymorphisms on Type 2 Diabetes: A Cross-Sectional Study.

Lapik I, Ranjit R, Galchenko A Rev Diabet Stud. 2021; 17(1):21-29.

PMID: 34289004 PMC: 9380098. DOI: 10.1900/RDS.2021.17.21.

Methylenetetrahydrofolate reductase gene polymorphism and risk of type 2 diabetes mellitus.

Zhong J, Rodriguez A, Yang N, Li L PLoS One. 2013; 8(9):e74521.

PMID: 24023947 PMC: 3762795. DOI: 10.1371/journal.pone.0074521.

References

Mager A, Lalezari S, Shohat T, Birnbaum Y, Adler Y, Magal N . Methylenetetrahydrofolate reductase genotypes and early-onset coronary artery disease. Circulation. 1999; 100(24):2406-10. DOI: 10.1161/01.cir.100.24.2406. View

Pancharuniti N, Lewis C, SAUBERLICH H, Perkins L, Go R, Alvarez J . Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr. 1994; 59(4):940-8. DOI: 10.1093/ajcn/59.4.940. View

Albaladejo M, Parra S, Fenollar M, Ruiz-Espejo F, Tebar J, Martinez P . Plasmatic homocysteine concentration and its relationship with complications associated to diabetes mellitus. Clin Chim Acta. 2002; 326(1-2):105-12. DOI: 10.1016/s0009-8981(02)00287-5. View

Jacobsen D, Gatautis V, Green R, Robinson K, Savon S, Secic M . Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem. 1994; 40(6):873-81. View

Jacques P, Bostom A, Williams R, Ellison R, Eckfeldt J, Rosenberg I . Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996; 93(1):7-9. DOI: 10.1161/01.cir.93.1.7. View

Hasegawa G, Obayashi H, Kamiuchi K, Nakai M, Kanatsuna T, Yamaguchi M . The association between end-stage diabetic nephropathy and methylenetetrahydrofolate reductase genotype with macroangiopathy in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2003; 111(3):132-8. DOI: 10.1055/s-2003-39785. View

Wollesen F, Brattstrom L, Refsum H, Ueland P, Berglund L, Berne C . Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int. 1999; 55(3):1028-35. DOI: 10.1046/j.1523-1755.1999.0550031028.x. View

Landgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A, Brattstrom L . Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Intern Med. 1995; 237(4):381-8. DOI: 10.1111/j.1365-2796.1995.tb01190.x. View

van Bockxmeer F, Mamotte C, Vasikaran S, Taylor R . Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation. 1997; 95(1):21-3. DOI: 10.1161/01.cir.95.1.21. View

10.

Scaglione L, Gambino R, Rolfo E, Lillaz E, Gai M, Cassader M . Plasma homocysteine, methylenetetrahydrofolate reductase gene polymorphism and carotid intima-media thickness in Italian type 2 diabetic patients. Eur J Clin Invest. 2002; 32(1):24-8. DOI: 10.1046/j.1365-2362.2002.00936.x. View

11.

Lanfredini M, Fiorina P, Peca M, Veronelli A, Mello A, Astorri E . Fasting and post-methionine load homocyst(e)ine values are correlated with microalbuminuria and could contribute to worsening vascular damage in non-insulin-dependent diabetes mellitus patients. Metabolism. 1998; 47(8):915-21. DOI: 10.1016/s0026-0495(98)90344-4. View

12.

Weisberg I, Tran P, Christensen B, Sibani S, Rozen R . A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab. 1998; 64(3):169-72. DOI: 10.1006/mgme.1998.2714. View

13.

Arruda V, von Zuben P, Chiaparini L, Annichino-Bizzacchi J, Costa F . The mutation Ala677-->Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost. 1997; 77(5):818-21. View

14.

Stabler S, Estacio R, Jeffers B, Cohen J, Allen R, Schrier R . Total homocysteine is associated with nephropathy in non-insulin-dependent diabetes mellitus. Metabolism. 1999; 48(9):1096-101. DOI: 10.1016/s0026-0495(99)90121-x. View

15.

Smulders Y, Rakic M, Slaats E, Treskes M, Sijbrands E, Odekerken D . Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care. 1999; 22(1):125-32. DOI: 10.2337/diacare.22.1.125. View

16.

Simon J, Mayer Jr O, Rosolova H . [Effect of folates, vitamin B12 and life style factors on mild hyperhomocysteinemia in a population sample]. Cas Lek Cesk. 2000; 138(21):650-3. View

17.

Schneider J, Rees D, Liu Y, Clegg J . Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet. 1998; 62(5):1258-60. PMC: 1377093. DOI: 10.1086/301836. View

18.

Frosst P, Blom H, Milos R, Goyette P, Sheppard C, Matthews R . A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995; 10(1):111-3. DOI: 10.1038/ng0595-111. View

19.

Upchurch Jr G, Welch G, Fabian A, Freedman J, Johnson J, Keaney Jr J . Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 1997; 272(27):17012-7. DOI: 10.1074/jbc.272.27.17012. View

20.

Hankey G, Eikelboom J . Homocysteine and vascular disease. Lancet. 1999; 354(9176):407-13. DOI: 10.1016/S0140-6736(98)11058-9. View